Since cyclooxygenase (COX) inhibitors have been pointed out as potential treatments to increase pregnancy rates after embryo transfer, the present experiment aimed to evaluate the effects of flunixin meglumine (FM) and parecoxib (P), a COX-1 and 2 or COX-2 specific inhibitor, respectively, on the development of bovine embryos until the hatched blastocyst stage. In vitro produced bovine embryos were cultured in media with different concentrations of FM (0.14; 1.4; 14; 140 or 1400 µg/ml) or P (0.09; 0.9; 9; 90 or 900 µg/ml) and the production rates were evaluated. Concentrations of FM ≤14 µg/ml and P ≤90 µg/ml did not impair embryo development, although compiled data from non-lethal FM concentrations (≤14 µg/ml) indicated a toxic effect enough to decrease the hatching rate of blastocysts. Concentrations of FM at 140 and 1400 µg/ml and P at 900 µg/ml were lethal as no cleavage was detected on presumptive zygotes.
Introduction
The relevance of the steroidal hormone progesterone (P4) on the establishment and maintenance of gestation is well documented (Wilmut et al., 1985; Binelli et al., 2001) , as is the relationship between plasma P4 concentrations and the corpus luteum (CL; Lamming et al., 1989; Binelli et al., 2004) . Briefly, when the CL is functionally active in the ovary (luteal phase), the concentration of P4 is high and the uterus is prepared for the establishment of pregnancy (Lamming et al., 1989; Shelton et al., 1990) . The conceptus must signal its presence via interferon-τ production, thus preventing luteolytic prostaglandin F2 (PGF2) pulses, which results in the maintenance of the CL and the continued release of progesterone (Binelli et al., 2001 (Binelli et al., , 2004 Nogueira et al., 2004) . Additionally, reports indicate a negative relationship between PGF2 concentrations and embryo quality (Schrick et al., 1993; Buford et al., 1996; Scenna et al., 2004a Scenna et al., , b, 2005 . Cyclooxygenase (COX) inhibitors are nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit PGF2 synthesis. The resulting antiluteolytic effect of NSAIDs make them potential tools for increasing pregnancy rates after embryo transfer (Binelli et al., 2001 (Binelli et al., , 2004 Schrick et al., 2001) . COX exists in two isoforms; COX-1, a constitutive enzyme present in many tissues, and COX-2, an inducible enzyme, mainly produced at the sites of inflammation, and is the key enzyme in the synthesis of PGF2 by its precursor, arachidonic acid (Thatcher et al., 2001) . Flunixin meglumine (FM), a nonselective COX-1/-2 inhibitor, and parecoxib (P), a specific COX-2 inhibitor, could be appropriately used to block COX-2 in an attempt to increase pregnancy rates in the bovine species. However, authors disagree on the concentrations and administration pathways for FM (Buford et al., 1996; Odensvik et al., 1998; Geary et al., 2005; Purcell et al., 2005; Scenna et al., 2005) , and the potential side effects of P have yet to be elucidated (Ayar, 2007) .
This study aimed to establish the embryotoxic threshold for concentrations of flunixin meglumine and parecoxib on the in vitro culture of bovine embryos. This approach was previously described to validate a model for pharmacological dose-response (Avery and Schmidt, 1995) .
Materials and Methods
Unless otherwise mentioned, all chemicals were obtained from Sigma-Aldrich Laboratory (St. Louis, MO, USA).
Abattoir location and animals
Ovaries from the Nelore breed (Bos indicus) were collected from a local abattoir (Frigol, Lençois Paulista, SP, Brazil, latitude 22 
Recovery of cumulus oocyte complexes
Cumulus oocyte complexes (COCs) were aspirated from small follicles (3-8 mm in diameter) using an 18-ga needle attached to a 10 ml syringe. Oocytes were classified according to their morphology (Khurana and Niemann, 2000) and the ones with a uniformly granulated cytoplasm and surrounded by several (3-4) layers of compact cumulus cells were selected and washed three times with HEPES-buffered TCM-199 medium containing fetal calf serum (FCS, 10%; Gibco, BRL, Burlington, Ontario, Canada), pyruvate (2 µl/ml, 100 mM solution) and gentamicin (75 µg/ml) then washed once with maturation medium.
In vitro maturation
Fifteen to 25 COCs were incubated in groups. Each droplet (90 µl) of maturation medium consisted of TCM-199 medium (Earle's salt) supplemented with sodium pyruvate (2 µl/ml, 100 mM solution), gentamicin (75 µg/ml), pFSH (20 µg/ml, Pluset ® , Serovet, Roma, Italy) and pLH (2 IU/ml, Lutropin ® , Bioniche, Belleville, Ontario, Canada). The droplets were covered with mineral oil (3.5 ml) and preincubated under the maturation conditions for a minimum of 2 h (39C, 5% CO 2 in air with 100% humidity) then incubated for 18 to 24 h once the COCs were added.
In vitro fertilization
In vitro fertilization (IVF) took place in droplets (90 l) containing tyrode albumin lactate pyruvate (TALP) supplemented with 6 mg/ml fatty acid free BSA, 100 mM sodium pyruvate, 75 g/ml gentamicin, 11 g/ml heparin and 44 g/ml PHE (2mM penicillamine, 1 mM hypotaurine and 250 mM epinephrine). Semen was thawed at 37C for 20 s and spermatozoa were washed in a discontinuous Percoll gradient (Pharmacia, Uppsala, Sweden) prepared by adding 2 ml of 45% Percoll to 2 ml of 90% Percoll in a 15 ml centrifuge tube (Corning ® ; 900 g; 30 min). After removal of the supernatant, spermatozoa were resuspended in IVF medium (1 x 10 6 cells/ml) and added into each droplet for incubation (39C; 5% CO 2 ; 10 to 14 h).
In vitro culture
Cumulus cells were removed from presumptive zygotes by vortexing the embryos in conical tubes containing TCM-199 medium with HEPES for 4 min. Cumulus-free presumptive zygotes were washed twice in TCM-199 medium with HEPES and transferred to 90 μl culture drops (15 to 25 zygotes per drop) under mineral oil. The culture medium consisted of synthetic oviduct fluid with amino acids, sodium citrate and myo-inositol (SOFaaci; Holm et al., 1999) plus FCS (5%; Gibco ® ), BSA (5%), and sodium pyruvate (0.2%), which was used to cultivate the embryos. A submarine incubation system, based on a previous experiment by Satrapa et al. (2011) , was used. Briefly, Petri dishes containing embryos were placed in plastic bags (25 x 15 cm) containing a gas mixture of 5% O 2 , 5% CO 2 and 90% N 2 (White Martins, São Paulo, SP, Brazil). The culture medium was partly replaced with 50 μl of fresh medium at 48, 96, 144 and 192 h after fertilization (Satrapa et al., 2011) . Before each medium replacement, cleavage, morula, blastocyst and hatched blastocyst yields were evaluated.
Drug concentrations
Presumptive zygotes were cultured as described before in the absence (control group) or presence of parecoxib (P; Bextra ® , injectable, 40 mg, Pfizer Pharmaceuticals, Barceloneta, Puerto Rico) or flunixin meglumine (FM; Banamine ® , injectable, 500 mg, Schering-Plough, Rio de Janeiro, Brazil). Standard concentrations were estimated by the usual dosage for embryo transfer in the bovine species (14 µg/ml FM; Geary et al., 2005; Purcell et al., 2005) and based on the maximum daily dosage of the prescription for a human being (i.e., 80 mg of P, according to drug information contents). The approach to define the P concentration for the bovine species was attempted using the average body weight of a human being (70 kg) and bovine (450 kg). Metabolic weights of humans (MWH = 70 0.75 ) and the bovine (MWB = 450 0.75 ) species were calculated (Keesey and Hirvonen, 1997) and the proportional concentration of P to MWH (80 mg/24.2 kg) was calculated for 97.7 kg of MWB (i.e., approximately 323 mg of P). Bovine blood volume was calculated based on an average body weight of 450 kg and an average of 8% blood volume (l) relative to body weight, that is, 36 l of blood (Reynolds, 1953; Aird et al., 2006) . Finally, P serum concentration in the bovine species was calculated by dividing total dosage (323 mg) by blood volume (36000 ml). The calculated P serum concentration (approximately 9 µg/ml) was used as the standard, and it could be the approximate P concentration of the uterine environment that the bovine embryo would be exposed to under real conditions of drug administration. For both drugs, decreased (x0.1 and x0.01) and increased (x10 and x100) concentrations were calculated relative to the standard P and FM concentrations (0.09; 0.9; 9; 90 and 900 µg/ml of parecoxib; 0.14; 1.4; 14; 140 and 1400 µg/ml of FM). During IVC, each culture dish had medium drops with all drug (P and FM) concentrations along with a control group (without the drug). When the medium was partially changed, the drug concentrations were maintained the same as the original drop concentration.
A pilot experiment (4 replicates) was performed to evaluate the embryo toxicity of the drug diluent itself (NaCl 0.9%) on bovine blastocyst and hatched blastocyst production. Only the diluents were added to the IVC medium, as the same volume would be used in the several different concentrations and IVC was done the same way as the P, FM and control groups.
Statistical analyses
Data were compared among concentrations (drug concentrations and respective control, i.e., intradrug comparison) by a Cochran-Armitage Trend Test (Armitage, 1955; Agresti, 2002) and by clustering non-lethal concentrations of the same drug to compare hatched blastocyst rates with their respective control group using Chi-square analysis (Yates correction for continuity). Significance was considered when P < 0.05.
Results
The results show data from 11 replicates for FM and 14 for P. However, for the FM concentrations of 140 and 1400 µg/ml and P concentration of 900 µg/ml, data are from 4 replicates only, since a lethal effect (i.e., arrested embryo development) was observed in these groups.
Parecoxib
Cleavage, morula, blastocyst and hatched blastocyst rates of all P concentrations are summarized in Table 1 . A concentration of 900 µg/ml was lethal for embryo development as early as the first cleavages (48 h post insemination). The other concentrations (0.09; 0.9; 9 and 90 µg/ml) showed no significant differences in blastocyst and hatched blastocyst rates when compared to the control group. only with concentrations ≤90 µg/ml. NA (not applicable) since after evaluation of morula rate, the presumptive zygotes were morphologically dead (dark color and/or fragmented and/or no visible cytoplasmic membrane) and were removed from the culture drops.
Flunixin meglumine
Cleavage, morula, blastocyst and hatched blastocyst rates of all FM concentrations are summarized in Table 2 . The two highest FM concentrations (140 and 1400 µg/ml) were lethal for embryo development as early as the first cleavage evaluation. However, the other concentrations had no significant difference when compared to the control group. only with concentrations ≤14 µg/ml. NA (not applicable) since after evaluation of morula rate, the presumptive zygotes were morphologically dead (dark color and/or fragmented and/or no visible cytoplasmic membrane) and were removed from the culture drops.
Pooled data
The first analysis comparing non-lethal drug concentrations showed no significant difference among themselves (0.09; 0.9; 9 and 90 µg/ml for P, and 0.14; 1.4 and 14 µg/ml for FM). Hence, these concentrations were clustered in groups (non-lethal concentrations; nlc) for each drug (nlcP and nlcFM). Control groups from both experiments (Control P and Control FM) remained as the original control group for each drug and hatched blastocyst rates were compared to the nlcP and nlcFM groups, respectively. There was a statistical difference (P < 0.003) between hatched blastocyst rates from the nlcFM (16.9%; 61/362) and Control FM (29.8%; 37/124) groups. There was no difference in hatched blastocysts rates (P = 0.09) between the nlcP (12.5%; 107/855) and Control P (17.0%; 42/247) groups.
Discussion
Some concentrations (FM: 0.14; 1.4 and 14 µg/ml; P: 0.09; 0.9; 9 and 90 µg/ml) did not affect cleavage and blastocyst production. However, higher concentrations (FM: 140 and 1400 µg/ml; P: 900 µg/ml) were lethal, as no presumptive zygotes cleaved under these conditions.
Attempts of FM administration to increase bovine pregnancy rates have already been reported. However, there was no consensus among these studies since in every experiment, neither the dosage, time nor the route of administration were consistent (Buford et al., 1996; Odensvik et al., 1998; Elli et al., 2001; Geary et al., 2005; Purcell et al., 2005; Scenna et al., 2005) . Additionally, there is insufficient published information regarding the pharmacological threshold of FM and P concentrations that may be toxic to bovine embryos. The in vivo use of any drug to modulate embryo development should first be tested for the embryotoxicity threshold using an in vitro model, similar to this study, to facilitate the usage of safe concentrations in vivo. The time that the embryos were exposed to drugs in this study (a maximum of 178 h on culture) may be considered an extreme condition compared with the shortest time (12 to 24 h) of regular treatment in cattle (Buford et al., 1996; Odensvik et al., 1998) . Regardless, and despite the unknown bioavailability of these drugs in the bovine uterine lumen, the present assay provides useful information for future in vivo experiments with intramuscular treatments of both FM and P in the bovine species. The analysis of pooled data from the non-lethal concentrations of P resulted in no decrease in the hatching rate (178 h of culture) compared with the control group, whereas with the non-lethal concentrations of FM, there was a significant difference between hatched blastocysts compared with the control group (16.9 and 29.8%, respectively). This finding could be interpreted as being due to the long time that the embryos were exposed to the drug until the hatching stage, and mainly due to the drug itself (i.e., its pharmacological properties) because this effect was not observed (P = 0.09). In a pilot experiment (results not shown), the vehicle used to dilute each drug was tested to evaluate its embryotoxicity, and no apparent harmful effects of the P or FM vehicle were observed. Since individual FM non-lethal concentrations did not differ from the control, it is difficult to infer which concentrations were the main effectors of potential embryotoxicity observed in the pooled data. This presumptive embryotoxicity could have arisen when concentrations were clustered, resulting in a robust sample large enough to produce a statistical difference between pooled FM data and the control. Moreover, the system of bovine IVP itself is a source of great variation in inter replicates (age, body condition, health status of animals), thus, both factors could explain the statistical difference observed only in the pooled FM data.
As previously described, this dose-response study could be the first screening for potential bovine embryotoxic effects of new drugs (usage of P in bovine embryo transfer). However, embryonic safety needs in vivo validation since unexpected in vivo effects could not be ruled out solely based on an in vitro model of embryotoxicity.
A flunixin meglumine concentration of 14 µg/ml (already employed in vivo as a strategy for increasing pregnancy rates in bovine recipients) was not toxic enough to inhibit the development of cultured bovine embryos, even after a long time of exposure. In addition, high concentrations of P (900 µg/ml) and FM (140 and 1400 µg/ml) were lethal as early as the first cleavage, i.e., under the effect of a few hours of drug exposure.
In conclusion, bovine embryo development was completely impaired with concentrations of 900 µg/ml parecoxib and 140 and 1400 µg/ml flunixin meglumine in the culture medium. When the non-lethal concentrations were compared, we inferred that parecoxib had a lower potential toxicity to decrease hatching rates after a long time of drug exposure (178 h) during culture. 
